NEWTON, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- 4D Path, a company dedicated to personalizing cancer care through a novel,…
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…